Cite
HARVARD Citation
Martini, D. et al. (n.d.). 637 Immune-related adverse events (irAEs) may indicate a favorable prognosis in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI). Journal for immunotherapy of cancer. pp. A380-A381. [Online].